NYSE:RMD
ResMed Inc. (RMD)
Financials 
Technical Analysis 
Sep 9, 2026, 12:00 amThis summary was created by AI, based on 2 opinions in the last 12 months.
ResMed Inc. (RMD) has been highlighted as a top pick by stock analysts, reflecting a strong market position in the CPAP machine sector, where it is recognized as a dominant player. Analysts note that there is a significant untapped market for CPAP machines, as consumers are typically hesitant to switch products once they have chosen one. The company's recent performance shows a commendable increase of up to 14% and even 10.1% in recent reviews. However, the stock has triggered a stop-loss recommendation at $244, indicating the necessity for investors to exercise caution and discipline in their trading strategies. Taking into account the potential synergy with weight loss drugs, ResMed's overall outlook presents a blend of opportunities and prudent investment considerations.
;fill-opacity:1;'/%3e%3cpath%20d='M31%2018.6001V30H8V18.6001L14.1334%2022.4334L19.4999%2014L24.8669%2022.4334L31%2018.6001Z'%20fill='%23EE5432'%20style='fill:%23EE5432;fill:color(display-p3%200.9340%200.3310%200.1956);fill-opacity:1;'/%3e%3c/svg%3e){kind=small}
Premium content
Premium contentResMed has beaten earnings four straight quarters, and its 31.2x PE is nowhere near its 2021 high of 74.5x. However, the street projects a lower future PE of 27.69x. The most recent EPS of $8.91 was 37.09% more than the previous year. Its ROE of 25.81% ranks among the highest in medical equipment where the average is 9.66%. A bonus is that the company operates within the U.S., so is protected from tariffs. Paying a dividend of only 0.76%, ResMed is one for growth, not income.
Premium contentRMD has been showing positive momentum recently, it is nearing in on its all-time highs, and forward margin expansion is expected to be quite positive. Analyst estimates are trending higher, its margins have been growing, and it generats strong free cash flow, which is partly used for dividends, buybacks, and growing the balance sheet. It is trading at a reasonable valuation of 25X forward earnings, and it has structural tailwinds. We would be comfortable buying the name here today for a long-term hold.
Unlock Premium - Try 5i Free
Premium contentPremium content
Premium contentRMD provides cloud based digital medical devices to assist with sleep and respiratory monitoring and treatment — a steady and reliable business model. It trades at 26x earnings and supports a respectable ROE of 25%. We like that cash reserves are growing, while debt is retired and shares bought back. We recommend setting a stop-loss at $190, looking to achieve $271 — upside potential of 22%. Yield 1.0%
(Analysts’ price target is $271.71)Gagdets like Goggle Watch have shown people how poorly they sleep. Resmed makes sleep apnea machines, which sees big, growing demand, and they hold 90% of the market.
(Analysts’ price target is $241.48)
Brendan Caldwell
18 million Americans have sleep apnea with many others undiagnosed. They have 2.5 billion nights of medical sleep data. They take cases out of hospitals and into homes. Based in Australia and the U.S. Shares have been been steadily rising. (1.3% dividend yield, Analysts' price target $109.75)
'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
Popular Articles
ResMed Inc. (RMD) Frequently Asked Questions
What is ResMed Inc. stock symbol?
ResMed Inc. is a American stock, trading under the symbol RMD (previously RMD-N on Stockchase) on the New York Stock Exchange (RMD). It is usually referred to as NYSE:RMD or RMD
Is ResMed Inc. a buy or a sell?
In the last year, 2 stock analysts issued a Buy, Sell, or Hold rating on RMD (previously RMD-N on Stockchase). 2 analysts recommended to BUY and 0 analysts recommended to SELL the stock. The latest stock analyst rating is PAST TOP PICK. Read the latest stock experts' ratings for ResMed Inc..
Is ResMed Inc. a good investment or a top pick?
ResMed Inc. was recommended as a Top Pick by The Panic-Proof Portfolio (Stockchase Research) on 2025-11-04. Read the latest stock experts ratings for ResMed Inc..
Why is ResMed Inc. stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for ResMed Inc..
Is ResMed Inc. worth watching?
ResMed Inc. is followed by 31 investors on Stockchase and is a trending stock that is worth watching.
What is ResMed Inc. stock price?
On 2026-09-09, ResMed Inc. (RMD) stock closed at a price of $219.95.
Our PAST TOP PICK with RMD has triggered its stop at $244. To remain disciplined, we recommend covering the position at this time.